During a Forbes health care summit, Mylan CEO Heather Bresch took full responsibility for the large price hikes on EpiPens, and reversed course on blaming pharmacy benefit managers for the price increases. Instead she said that there’s “distance in the drug chain” between the price a manufacturer places on a drug and what it ends up costing consumers out-of-pocket.